Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
You may also be interested in...
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.